Compare BLK & JNJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BLK | JNJ |
|---|---|---|
| Founded | 1988 | 1886 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 164.2B | 542.4B |
| IPO Year | 2024 | 2003 |
| Metric | BLK | JNJ |
|---|---|---|
| Price | $985.55 | $239.51 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 20 |
| Target Price | ★ $1,275.21 | $238.20 |
| AVG Volume (30 Days) | 693.3K | ★ 7.4M |
| Earning Date | 04-14-2026 | 04-14-2026 |
| Dividend Yield | 2.21% | ★ 2.36% |
| EPS Growth | N/A | ★ 90.50 |
| EPS | ★ 14.06 | 2.14 |
| Revenue | ★ $12,794,000,000.00 | N/A |
| Revenue This Year | $16.98 | $6.63 |
| Revenue Next Year | $10.72 | $7.43 |
| P/E Ratio | ★ $72.28 | $111.72 |
| Revenue Growth | ★ 16.18 | N/A |
| 52 Week Low | $917.39 | $151.01 |
| 52 Week High | $1,219.94 | $251.71 |
| Indicator | BLK | JNJ |
|---|---|---|
| Relative Strength Index (RSI) | 37.32 | 59.22 |
| Support Level | $987.16 | $233.83 |
| Resistance Level | $992.13 | $244.80 |
| Average True Range (ATR) | 25.99 | 4.73 |
| MACD | -1.22 | 0.43 |
| Stochastic Oscillator | 16.10 | 77.95 |
BlackRock is the largest asset manager in the world, with $14.041 trillion in assets under management at the end of December 2025. Its product mix is diverse, with 55% of managed assets in equity strategies, 23% in fixed income, 9% in multi-asset classes, 6% in money market funds, and 5% in alternatives. Passive strategies account for more than two-thirds of long-term AUM, with the company's ETF platform maintaining a leading market share domestically and on a global basis. Product distribution is weighted more toward institutional clients, which, by our calculations, account for around 80% of AUM. BlackRock is geographically diverse, with clients in more than 100 countries and more than one-third of managed assets coming from investors domiciled outside the US and Canada.
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.